This episode covers pivotal regulatory developments influencing key sectors such as Nipocalimab, Compliance, Inflation, Initial Access List, and BPR within ASEAN.

Listeners will gain insights on the Bangko Sentral ng Pilipinas' decision to raise the reverse repurchase rate by 25 basis points to 4.5%, signaling an end to the easing cycle and possible further hikes. Financial institutions must recalibrate lending and borrowing policies accordingly.

Another major update includes the awarding of the Public Waste Collection Licence for Singapore’s Zone 6 Pasir Ris-Bedok sector to 800 Super Waste Management Pte Ltd, introducing a modernized fleet with electric trucks and expanded recyclables collection.

In Indonesia, the Indonesia Deposit Insurance Corporation (LPS) has announced critical deadlines and processes for deposit guarantee payments concerning revoked banks such as PT BPR Bumi Pendawa Raharja, Perumda BPR Bank Cirebon, and PT BPR Sumber Usahawan Bersama, emphasizing phased payments, claim submissions, and dispute protocols.

For more information, visit the Carver Agents website.

Articles mentioned:

1. Bangko Sentral ng Pilipinas raises rates, signals more hikes
2. New Public Waste Collection Licence for the Zone 6 (Pasir Ris-Bedok) Sector Commences 1 July 2026
3. Pengumuman Pembayaran Atas Penetapan Status Penjaminan Simpanan Nasabah Penyimpan PT BPR Bumi Pendawa Raharja (DL) Tahap 3
4. Pengumuman Pembayaran Atas Penetapan Status Penjaminan Simpanan Nasabah Penyimpan Perumda BPR Bank Cirebon (DL)
5. Bedding supplier Emma Sleep to pay a total of $15m in penalties for misleading statements about sale prices
6. Pengumuman Pengajuan Keberatan Nasabah Penyimpan atas Penetapan Status Penjaminan Simpanan Nasabah PT BPR Bumi Pendawa Raharja (DL)
7. Bangko Sentral ng Pilipinas Discount Window Facility interest rates effective 27 April 2026
8. Pengumuman Batas Waktu Pengajuan Klaim Penjaminan Simpanan Layak Dibayar Nasabah Penyimpan PT BPR Sumber Usahawan Bersama (DL)
9. Notice of Extension: Public Consultation for the Initial Access List
10. Kurzbericht Zulassung – Imaavy®